1-4 of 4
Wayne J. Fairbrother
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Free
Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, Amy Young, Michael Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Peng Yue, Jason Oeh, Leslie Lee, Sophie Maiga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 1132–1144.
https://doi.org/10.1158/1535-7163.MCT-15-0730
Published: 05 May 2016
View articletitled, Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Open the PDF for Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models in another window
Includes: Supplementary data
Journal Articles

Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

Free
Deepak Sampath, Sylvia Herter, Ellen Ingalla, Frank Herting, Marina Bacac, Michelle Nannini, Wayne J. Fairbrother, Christian Klein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A245.
https://doi.org/10.1158/1535-7163.TARG-13-A245
Published: 01 November 2013
View articletitled, Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
Journal Articles

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Free
Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother, Lisa D. Belmont
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2013) 12 (6): 853–864.
https://doi.org/10.1158/1535-7163.MCT-12-0949
Published: 09 June 2013
View articletitled, Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Open the PDF for Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models in another window
Includes: Supplementary data
Journal Articles

Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

Free
Maureen Wong, Nguyen Tan, Jiping Zha, Franklin V. Peale, Peng Yue, Wayne J. Fairbrother, Lisa D. Belmont
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 1026–1035.
https://doi.org/10.1158/1535-7163.MCT-11-0693
Published: 08 April 2012
View articletitled, Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models
Open the PDF for Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models in another window
Includes: Supplementary data